Sigma-Aldrich to Acquire
Proligo; Shelves India Facility

Sigma-Aldrich plans to purchase DNA and RNA maker Proligo from Degussa, the company said this week.

Proligo, headquartered in Boulder, Colo., provides custom DNA, RNA, and raw materials for DNA and RNA synthesis. The company is one of four exclusive licensees to an RNAi patent application owned by MIT.

Last year, Proligo had approximately $40 million in sales. The 300-employee company has manufacturing sites in Boulder, France, Germany, Singapore, Japan, and Australia.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.